Indications for: KIMYRSA
Susceptible acute bacterial skin and skin structure infections (ABSSSI).
Give by IV infusion over 1hr. ≥18yrs: 1200mg as a single dose.
<18yrs: not established.
Use of IV unfractionated heparin sodium for 120hrs (5 days) after oritavancin administration.
History of glycopeptide allergy. Discontinue immediately if acute hypersensitivity reaction occurs. Consider stopping or slowing infusion if infusion-related reactions occur. Evaluate if Clostridioides difficile-associated diarrhea is suspected or confirmed. Monitor for osteomyelitis; use alternative therapy if suspected or diagnosed. Severe hepatic or renal impairment: not studied. Pregnancy. Nursing mothers.
Increased risk of bleeding with concomitant warfarin; may prolong aPTT for up to 120hrs, PT/INR for up to 12hrs, and ACT for up to 24hrs; monitor for bleeding. Avoid concomitant with drugs that are predominantly metabolized by one of the affected CYP450 enzymes. May increase concentrations of CYP2C9/CYP2C19 substrates. May decrease concentrations of CYP3A4/CYP2D6 substrates. May interfere with coagulation tests; consider non-phospholipid dependent test (eg, Factor Xa assay) or alternative anticoagulant not requiring aPTT monitoring.
Headache, nausea, vomiting, limb and subcutaneous abscesses, diarrhea; infusion-related reactions.
Generic Drug Availability: